DISCUSSION
tumor, tumors
ONCOGENESIS, REGRESSION, TUMOR, TUMORS
The efficacy of PI3K inhibitors has been confirmed in randomized phase 3 trials.The safety profile of pan‐PI3K inhibitors has been a limiting factor for their use in clinical practice.HS‐10352 exhibited favorable pharmacokinetic characteristics. According to the concentration–time curves, an increase in dosage did not correspondingly elevate the trough concentration after multiple administrations. Notably, the plasma level of HS‐10352 at an 8 mg dose appeared to plateau, suggesting dose saturation.PIK3CA mutations often result in hyperactivation of the PI3K/AKT/mTOR pathway, which is associated with oncogenesis, tumor development, and resistance to endocrine therapy in HR‐positive, HER2‐negative ABC.Given that inhibitors of the PI3K/AKT/mTOR pathway can mitigate endocrine therapy resistance in HR‐positive, HER2‐negative ABC, combination therapy emerges as a compelling strategy. Agents like fulvestrant can notably enhance the sensitivity of ER‐positive tumors to PI3Kα inhibition, thereby facilitating substantial tumor regression in vivo.Despite exhibiting a higher response rate compared with other PI3K/AKT/mTOR pathway inhibitors used as monotherapies in previous reports,